Biofrontera Inc. price target adjusted to $18 at Benchmark after reverse split

Benchmark analyst Bruce Jackson adjusted the firm’s price target on Biofrontera Inc. to $18 from $140 and keeps a Buy rating on the shares after the company effected a 1-for-20 reverse stock split of its outstanding shares of common stock.